Monitoring molecular markers associated with antimalarial drug resistance in south-east Senegal from 2021 to 2023
Wade A, Sene S, Caspar E, Diallo F, Platon L, Thiebaut L, Pouye M, Ba A, Thiam L, Fall M, Sadio B, Desamours I, Guerra N, Hagadorn K, Amambua-Ngwa A, Bei A, Vigan-Womas I, Ménard D, Mbengue A. Monitoring molecular markers associated with antimalarial drug resistance in south-east Senegal from 2021 to 2023. Journal Of Antimicrobial Chemotherapy 2025, 80: 828-839. PMID: 39846779, PMCID: PMC11879165, DOI: 10.1093/jac/dkaf006.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntimalarialsArtemisininsChildChild, PreschoolDrug CombinationsDrug ResistanceFemaleHumansMalaria, FalciparumMaleMembrane Transport ProteinsMiddle AgedMultidrug Resistance-Associated ProteinsMutationPlasmodium falciparumProtozoan ProteinsPyrimethamineSenegalSulfadoxineTetrahydrofolate DehydrogenaseYoung AdultConceptsArtemisinin-based combination therapyMolecular markers associated with antimalarial drug resistanceArtemisinin-based combination therapy efficacyP. falciparum infectionSulfadoxine-pyrimethamine resistanceAntimalarial drug resistanceInvestigated gene polymorphismsCQ-RResistance in vitroVenous blood samplesClinical outcome studiesI356TK76TPfcrt mutationsChloroquine resistanceAntimalarial resistancePfmdr-1CQ useMalaria eliminationCombination therapyResistance surveillanceGene polymorphismsPlasmodium falciparumDrug resistanceAmplicon deep sequencing
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply